Hypersensitivity Reactions to Biological Drugs

Seminars in Oncology Nursing

Volumn 23, Issue 3, 2007, Pages 191-200

  Gobel, Barbara Holmes ^a  

^a NONE

Author keywords

biological therapy; Hypersensitivity; nursing care

Indexed keywords

BIOLOGICAL FACTOR;

ARTICLE; CLASSIFICATION; DRUG HYPERSENSITIVITY; HUMAN;

BIOLOGICAL FACTORS; DRUG HYPERSENSITIVITY; HUMANS;

EID: 34547659382     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.05.009     Document Type: Article

References (54)

1. Riedl M.A., and Casillas A.M. Adverse drug reactions: types and treatment options. Am Fam Physician 68 (2003) 1781-1790
2. deShazo R.D., and Kemp S.F. Allergic reactions to drugs and biologic agents. JAMA 278 (1997) 1895-1906
3. Weiss R.B. Miscellaneous toxicities. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. Ed 6 (2001), Lippincott Williams and Wilkins, Philadelphia, PA 2964-2976
4. Shepherd G.M. Hypersensitivity reactions to drugs: evaluation and management. Mount Sinai J Med 70 (2003) 113-125
5. Gobel B.G. Chemotherapy-induced hypersensitivity reactions. Oncol Nurs Forum 32 (2005) 1027-1035
6. Ream M., and Tunison D. Hypersensitivity reactions. In: Yasko J.M. (Ed). Nursing management of symptoms associated with chemotherapy. Ed 5 (2001), Meniscus Limited, Bala Cynwyd, PA 271-282
7. Thomas M. Treatment-related hypersensitivity reactions to antineoplastic agents. recognition, prevention, and management [Continuing education monograph and self-test] (2004), American Academy of Continuing Medical Education, Skillman, NJ
8. Winkler U., Jensen M., Manzke O., et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999) 2217-2224
9. Ditto A.M. Drug allergy, part A: Introduction, epidemiology, classification of adverse reactions, immunochemical basis, risk factors, evaluation of patients with suspected drug allergy, patient management considerations. In: Grammer L.C., and Greenberger P.A. (Eds). Patterson's allergic diseases. Ed 6 (2002), Lippincott Williams and Wilkins, Philadelphia, PA 295-334
10. Barranco P., and Lopez-Serrano M.C. General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy 28 suppl 4 (1998) 61-62
11. Bayard P.J., Berger T.G., and Jacobson M.A. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 5 (1992) 1237-1257
12. Descamps V., Valance A., Edlinger C., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 137 (2001) 301-304
13. Lang D.M., Alpern M.B., Visintainer P.F., et al. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 115 (1991) 270-276
14. Petri M., and Allbritton J. Antibiotic allergy in systemic lupus erythematous: a case-control study. J Rheumatol 19 (1992) 265-269
15. Adkinson Jr. N.F. Risk factors for drug allergy. J Allergy Clin Immunol 74 (1984) 567-572
16. Cheng J.D., Rieger P.T., von Mehren M., et al. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 16 suppl 1 (2000) 2-12
17. Rieger P.T., Green M., and Murray L. Monoclonal antibodies: Applications in solid tumors and other diseases. In: Rieger P.T. (Ed). Biotherapy (2001), Jones and Bartlett, Sudbury, MA 317-355
18. National Cancer Institute. Common terminology criteria for adverse events v 3.0 (2003). http://ctep.cancer.gov/reporting/ctc.html Available at. http://ctep.cancer.gov/reporting/ctc.html (accessed December 18, 2006).
19. Zanotti K.M., and Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety 24 (2001) 767-779
20. Drain K.L., and Volcheck G.W. Preventing and managing drug-induced anaphylaxis. Drug Safety 24 (2001) 843-853
21. Lieberman P., Kemp S.F., Oppenheimer J., et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 115 (2005) S483-S523
22. Labovich T.M. Acute hypersensitivity reactions to chemotherapy. Semin Oncol Nurs 15 (1999) 222-231
23. Yeung S., and Escalante C.P. Oncologic emergencies. In: Kufe D.W., Pollock R.E., Weichselbaum R.R., et al. (Eds). Holland-Frei Cancer Medicine. Ed 5 (2000), BC Decker Inc, Hamilton, Ontario 2659-2670
24. Busam K.J., Capodieci P., Motzer R., et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
25. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
26. Monti M., Mancini L.L., Ferrari B., et al. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 21 (2003) 4651-4653
27. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
28. Raben D., Helfrich B.A., Chan D., et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29 suppl 4 (2002) 37-46
29. van Doorn R., Kirtschig G., Scheffer E., et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa) an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147 (2002) 598-601
30. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology 17 (2003) 23-28
31. Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol 5 (2004) 647
32. In: Polovich M., White J.M., and Kelleher L.O. (Eds). Chemotherapy and biotherapy guidelines and recommendations for practice. Ed 2 (2005), Oncology Nursing Society, Pittsburgh, PA
33. In: Wilkes G.M., and Barton-Burke M. (Eds). Oncology nursing drug handbook (2005), Jones and Bartlett, Sudbury, MA
34. In: Fischer D.S., Knobf M.T., Durivage H.J., et al. (Eds). The cancer chemotherapy handbook. Ed 6 (2003), Mosby, Philadelphia, PA
35. Foss F.M., Bacha P., Osann K.E., et al. Biological correlates of acute hypersensitivity events with DAB (389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 1 (2001) 298-302
36. Olsen E.D., Duvic M., Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2001) 376-388
37. Osterborg A., Dyer M.J.S., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. J Clin Oncol 15 (1997) 1567-1574
38. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2334-2342
39. Clinical pharmacology. Cetuximab (2006). http://cpip.gsm.com Available at. http://cpip.gsm.com (accessed January 5, 2007).
40. Herbst R.S., and Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-225 in the treatment of lung and head and neck cancers. Semin Oncol 29 suppl 4 (2002) 27-36
41. Sievers E.L., Larson R.A., Stadtmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19 (2001) 3244-3254
42. Clinical pharmacology. Gemtuzumab ozogamicin (2006). http://cpip.gsm.com Available at. http://cpip.gsm.com (accessed January 5, 2007).
43. Wiseman G.A., White C.A., Witzig T.E., et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5 (1999) 3281s-3286s
44. DeNardo G. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 35 (2002) 202-211
45. Vectibix (Panitumumab). Full prescribing information (2007), Amgen Inc, Thousand Oaks, CA
46. Rituxan (Rituximab). Full prescribing information (2002), Genentech, Inc, South San Francisco, CA Revised February 2002.
47. Maloney D.G., and McLaughlin P. Rituximab for the treatment of patients with B-cell non-Hodgkin's lymphoma. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Progress in oncology (2001), Jones & Bartlett, Boston, MA 204-227
48. Plosker G.L., and Figgitt D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 63 (2003) 803-843
49. Kaminski M.S., Tuck M., Estes J., et al. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
50. Clinical pharmacology. Interferon alfa (2006). http://cpip.gsm.com Available at. http://cpip.gsm.com (accessed January 5, 2007).
51. Clinical pharmacology. Aldesleukin (2006). http://cpip.gsm.com Available at. http://cpip.gsm.com (accessed January 5, 2007).
52. Runge J.W., Martinez J.C., Caravati E.M., et al. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 21 (1992) 237-242
53. Joint Task Force on Practice Parameters. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allerg Clin Immunol 3 suppl 2 (2005) S438-S524
54. Brown A.F. Therapeutic controversies in the management of acute anaphylaxis. J Acc Emerg Med 15 (1998) 89-95